Here, we specifically investigated for the first time the genome-wide transcriptional targets of HOXA9 in four independent GBM cell models, and evaluated how HOXA9 affects critical cellular and molecular processes of the malignant phenotype of gliomas, using a combination of in vitro and in vivo models. This evidence concerns the gene HOXA9 and central nervous system cancer.